By Bob DeMarco
Rember bloody upon to a Alzheimer's scene in 2008. No headlines as well as not a single press recover from a company given Jul 2008. Not until today.
The Express.co.uk is reporting which Taurx is looking 80 million pounds to account outrageous clinical trials in a U.S. as well as U.K. The essay fundamentally regurgitates a same inform as well as sensational claims which were first made in July, 2008.
_________________________________________
TauRx Therapeutics was a large hit during a International Conference upon Alzheimer's Disease (ICAD) in 2008. They reported upon an extraordinary brand brand brand brand new experiment Alzheimer's drug -- rember.
The headlines recover direct from ICAD created a tidal call of press as well as headlines upon television when a company made this claim:
New investigate commentary point to a brand brand brand brand new diagnosis which appears to delayed a progress of Alzheimer's by 81% over a year. The product - rember - is a first drug to action to detain a progression of Alzheimer's mildew by targeting a tangles which have been rarely correlated with a disease.With a imprimatur of a Alzheimer's Association, experts hailing a study as a vital growth in a quarrel opposite Alzheimer's, as well as a lead scientist Dr. Claude Wischik of a University of Aberdeen raving, one could have resolved which a heal for Alzheimer's was possible.
We have demonstrated for a first time which it may be possible to detain progression of a mildew by targeting a tangles which have been rarely correlated with a disease, Professor Wischik said. This is a most significant growth in a diagnosis of a tangles given Alois Alzheimer discovered them in 1907.
And then, a story died. Not a single story or square of inform which a experimental drug contrast was moving forward.
A discerning check of a TauRx website will yield nothing. It appears which a last time a site was updated was upon Jul 30, 2008. The date of a announcement. The site itself was thrown up in promptness as well as is reduction than impressive.
A poke upon a Alzheimer's Association website yields zero brand brand brand brand new given Jul 30, 2008. In fact a couple to a ICAD press recover is broken, no longer available.
As an x-Wall Street try capitalist we have been wondering for some time because didn't this company embrace immediate financing for a phase 3 clinical trial?
One reason could be because there has never been a judgment published about rember in a systematic journal.
Another reason which comes to mind could be which a drug is a ostensible brand brand brand brand new plan of an existent containing alkali substance methylene blue. Among alternative ailments MTC has been used in a past to provide urinary tract infections as well as alternative conditions. Could a brand brand brand brand new plan of something which has been around for thirty years actually be patented? Stranger things have happened, so I'll leave which one to a attorney's.
I did consider getting a compound manufactured as well as perplexing it upon my mother. After all a referred to dose is now in a open domain -- twenty mg, three times a day.
A word of notice here, it turns your pee blue. This lead to one interesting comment we read. The writer speculated, how do we run a stand in blind clinical hearing if your pee turns blue. Did a placebo also spin a urine of a control group blue? If not, it would be pretty easy to know if we were receiving a drug or a placebo.
I cannot find any justification which TauRx has been postulated approval by a FDA to conduct a Phase 3 clinical trial. Impossible to raise capital under those circumstances.
One has to consternation if a Alzheimer's Association performed any due industry prior to usurpation a paper for ICAD 2008. After all, it was a Alzheimer's Association acceptance of a scholarship as well as press recover which triggered a headlines frenzy which followed.
Perhaps they can inform us of a current state of affairs, as well as because a clinical trials have been not moving forward.
Rember was heralded as a possible heal for Alzheimer's.
Professor Wischik has been working upon this for twenty-six years, his words.
Medpage Today did run an excellent inform upon rember as well as a claims of a scientist back in July, 2008.
FAQ about Rember as well as TauRx Therapeutics
Bob DeMarco is a editor of a Alzheimer's Reading Room as well as an Alzheimer's caregiver. Bob has created some-more than 1,200 articles with some-more than 9,000 links upon a Internet. Bob resides in Delray Beach, FL.Popular articles upon a Alzheimer's Reading Room
- Advice as well as Insight -- Alzheimer's Reading Room
- Dealing with Difficult Behavior Caused by Dementia as well as Alzheimer's
- Communicating in Alzheimer's World
- Dr Oz Alzheimer's Memory Quiz (Test)
- What is Alzheimer's Disease?
- Does a Combination of Aricept as well as Namenda Help Slow a Rate of Decline in Alzheimer's Patients
- Test Your Memory (TYM) for Alzheimer's or Dementia in Five Minutes
- Alzheimer's World -- Two Circles Trying to Intersect
- Baby Boomer Alzheimer's Perspective
- Alzheimer's Disease -- The Front Row
- Is it Really Alzheimer's or Something Else?
- Alzheimer's Clock Draw Test -- Detect a Signs of Alzheimer's Early
- 60 Good Reasons to Subscribe to a Alzheimer's Reading Room
"I Remember Better When we Paint"Subscribe to The Alzheimer's Reading Room
Original calm Bob DeMarco, a Alzheimer's Reading Room
No comments:
Post a Comment